Historical Stock Chart
2 Months : From Dec 2019 to Feb 2020
By Stephen Nakrosis
Illumina Inc. (ILMN) Monday said it entered a non-exclusive agreement with Roche to accelerate the use of genomics for medical diagnosis.
Illumina and Roche announced a 15-year, non-exclusive agreement to "broaden the adoption of distributable next-generation sequencing-based testing in oncology."
Under the terms of the deal, Roche will receive rights to develop and distribute in-vitro diagnostic tests using Illumina technology, such as the NextSeq 550DX System. Illumina said Roche will develop, manufacture and commercialize AVENIO IVD tests for use on the NextSeq 550Dx System. Illumina will continue to sell the system and core sequencing consumables, it said.
Roche will also work to complement Illumina's TruSight Oncology 500 pan-cancer assay, the companies said.
Financial terms of the deal weren't disclosed.
Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires
January 13, 2020 12:59 ET (17:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.